농장 동물 의료 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the farm animal healthcare market size was valued at USD 23.58 billion in 2025 and estimated to grow from USD 24.77 billion in 2026 to reach USD 31.69 billion by 2031, at a CAGR of 5.06% during the forecast period (2026-2031).

This report is Segmented by Product (Vaccines, Parasiticides, Anti-Infectives, and More), Animal Type (Cattle, Swine, and More), Route of Administration (Oral, Parenteral, and More), Distribution Channel (Veterinary Hospitals, Veterinary Clinics, and More), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Farm Animal Healthcare Market Trends and Insights

Advanced Technology Accelerating On-Farm Diagnostics

Portable PCR units and smartphone biosensors now allow barn-side pathogen detection within minutes, reducing outbreak response time from 72 hours to under 12 hours in systems such as Korea's KAHIS platform. Faster diagnosis drives timely treatment, curbs losses, and lifts demand for connected devices that integrate seamlessly with herd-management software. Adoption is most pronounced in North America and Western Europe where capital budgets and broadband coverage are strong. Device makers enjoy recurring revenue through reagent cartridges and data-subscription services. Wider rollout to remote regions hinges on affordable hardware and robust cold-chain logistics for test kits.

Government and Animal Welfare Vaccination Mandates

The European Union's African Swine Fever program and the USDA National Poultry Improvement Plan obligate commercial farms to follow strict immunization schedules. These rules create steady vaccine demand, favor firms with regulatory compliance expertise, and raise entry barriers for generic suppliers. Mandatory programs also spur investment in cold-chain infrastructure and automated mass-vaccination equipment. Emerging economies mirror these policies to secure export certifications, further enlarging the Farm Animal Healthcare market. However, smallholders face higher operating costs and need subsidies or cooperative models to comply.

Counterfeit and Sub-Standard Medicines

Substandard products account for 10-15% of global veterinary supply, eroding farmer confidence and fostering antimicrobial resistance. Enforcement raids, such as a USD 2.4 million vaccine seizure in Texas, spotlight the scale of illicit trade. Legitimate firms must invest in serialization, blockchain tracking, and education campaigns, raising operating costs. Emerging markets bear the brunt due to limited oversight and porous borders, which slows legitimate market entry and keeps the Farm Animal Healthcare market from achieving its full potential.

Other drivers and restraints analyzed in the detailed report include:

1. Growing Threat of Emerging Zoonoses
2. Shift Toward Preventive Biologics and Integrated Health Plans
3. Rising Costs of Veterinary Services and Testing

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

The vaccine segment's 7.31% CAGR through 2031 underscores a decisive transition to prevention as anti-infectives, despite a 37.02% 2025 revenue lead, face stewardship pressure. Farm Animal Healthcare market size gains stem from mRNA platforms, novel adjuvants, and automated delivery systems that cut labor costs. Manufacturers leverage premium pricing on differentiated biologics, offsetting margins lost to generic antibiotics. Parasiticides keep stable growth as expanding vector ranges threaten grazing herds, while medicinal feed additives face stricter residue rules that trim demand.

Autogenous vaccines expand quickly within the wider vaccine portfolio. Facilities in Brazil and Australia shorten supply chains and customize antigens to farm-specific pathogens, enhancing efficacy and commanding higher prices. Anti-infectives pivot to combination formulations and slow-release injectables to sustain differentiation. Diagnostic manufacturers partner with biologics suppliers to bundle herd-health packages, further boosting Farm Animal Healthcare market penetration.

Poultry maintained a 38.10% revenue share in 2025 as intensive broiler and layer systems standardize vaccination and biosecurity protocols. The cattle segment, however, leads future growth at a 6.61% CAGR, driven by dairy consolidation and precision farming tools that pinpoint mastitis or respiratory flare-ups early. Farm Animal Healthcare market size for cattle products is set to expand as wearable sensors and AI analytics enable targeted dosing and optimize reproductive performance.

Swine producers grapple with persistent African Swine Fever risks, steering investment toward robust biosecurity and multivalent vaccines. Sheep and goat health remains niche, though targeted parasite control products find traction in arid regions. Aquaculture cross-over technologies gain attention as land-based farmers diversify, enlarging the Farm Animal Healthcare market beyond terrestrial species.

Complete Report Scope:

• By Product
  • Vaccines
  • Parasiticides
  • Anti-infectives
  • Medicinal Feed Additives
  • Other Products
• By Animal Type
  • Cattle
  • Swine
  • Poultry
  • Sheep & Goats
  • Other Animal Types
• By Route of Administration
  • Oral
  • Parenteral
  • Topical
  • Other Route of Administrations
• By Distribution Channel
  • Veterinary Hospitals
  • Veterinary Clinics
  • Pharmacies & Drug Stores
  • E-commerce
  • On-farm Direct
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America
      • GCC

Geography Analysis

North America, holding 42.70% revenue in 2025, benefits from strong R&D ecosystems, established reimbursement for veterinary services, and early adoption of AI-based surveillance. Ongoing rural veterinarian shortages, though, threaten service coverage and may temper Farm Animal Healthcare market growth in frontier counties. Federal loan-forgiveness programs and mobile clinic initiatives aim to mitigate the gap.

Asia-Pacific leads growth with a 6.39% CAGR through 2031 as China modernizes mega-farms and India scales dairy cooperatives. Regulatory reforms that streamline dossier reviews and recognize international Good Manufacturing Practice certificates improve market entry timelines. Yet diverse languages and non-uniform biosecurity rules continue to complicate commercialization strategies.

Europe sustains moderate gains under strict welfare legislation and comprehensive vaccination mandates. Producers invest in premium biologics and diagnostics to satisfy export-market residue tolerances. Eastern member states allocate EU recovery funds to upgrade cold-chain logistics, broadening Farm Animal Healthcare market access.

South America and the Middle East and Africa represent high-potential, early-stage markets. Brazil and Argentina deploy autogenous vaccine capacity aimed at endemic strains, while Gulf states invest in food-security programs that include large-scale dairy and poultry ventures. Regulatory capacity constraints and counterfeit-product infiltration remain hurdles yet gradual harmonization under trade blocs such as Mercosur offers a clearer path for Farm Animal Healthcare market expansion.

1. Bayer Animal Health
2. Bimeda
3. Boehringer Ingelheim
4. Ceva Sante Animale
5. Dechra Pharmaceuticals
6. Elanco
7. Hester Biosciences
8. Huvepharma
9. Indian Immunologicals
10. Intas Pharmaceuticals
11. Merck
12. Norbrook
13. Ouro Fino Saude Animal
14. Phibro Animal Health
15. Vetoquinol
16. Virbac
17. Virbac South Africa

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Advanced Technology Accelerating On-Farm Diagnostics
  • 4.2.2 Government & Animal-Welfare Vaccination Mandates
  • 4.2.3 Growing Threat of Emerging Zoonoses
  • 4.2.4 Shift Toward Preventive Biologics & Integrated Health Plans
  • 4.2.5 AI-Enabled Real-Time Disease-Surveillance Platforms (Under-The-Radar)
  • 4.2.6 Autogenous-Vaccine CDMO Investments In Emerging Markets (Under-The-Radar)
• 4.3 Market Restraints
  • 4.3.1 Counterfeit & Sub-Standard Medicines
  • 4.3.2 Rising Costs Of Veterinary Services & Testing
  • 4.3.3 Acute Rural-Veterinarian Shortage After U.S. FDA GFI-263 (Under-The-Radar)
  • 4.3.4 Fragmented Regulatory Harmonisation In Lmics Delaying Launches (Under-The-Radar)
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Bargaining Power of Suppliers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Industry Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Product
  • 5.1.1 Vaccines
  • 5.1.2 Parasiticides
  • 5.1.3 Anti-infectives
  • 5.1.4 Medicinal Feed Additives
  • 5.1.5 Other Products
• 5.2 By Animal Type
  • 5.2.1 Cattle
  • 5.2.2 Swine
  • 5.2.3 Poultry
  • 5.2.4 Sheep & Goats
  • 5.2.5 Other Animal Types
• 5.3 By Route of Administration
  • 5.3.1 Oral
  • 5.3.2 Parenteral
  • 5.3.3 Topical
  • 5.3.4 Other Route of Administrations
• 5.4 By Distribution Channel
  • 5.4.1 Veterinary Hospitals
  • 5.4.2 Veterinary Clinics
  • 5.4.3 Pharmacies & Drug Stores
  • 5.4.4 E-commerce
  • 5.4.5 On-farm Direct
• 5.5 Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East & Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East & Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America
      • 5.5.5.3.1 GCC

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, Recent Developments)
  • 6.3.1 Bayer Animal Health
  • 6.3.2 Bimeda
  • 6.3.3 Boehringer Ingelheim Animal Health
  • 6.3.4 Ceva Sante Animale
  • 6.3.5 Dechra Pharmaceuticals
  • 6.3.6 Elanco
  • 6.3.7 Hester Biosciences
  • 6.3.8 Huvepharma
  • 6.3.9 Indian Immunologicals
  • 6.3.10 Intas Pharmaceuticals
  • 6.3.11 Merck Animal Health
  • 6.3.12 Norbrook
  • 6.3.13 Ouro Fino Saude Animal
  • 6.3.14 Phibro Animal Health
  • 6.3.15 Vetoquinol
  • 6.3.16 Virbac
  • 6.3.17 Virbac South Africa

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment